Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) stock is trading lower after the company reported third-quarter earnings.

Alnylam also said that it received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts seeking documents about government price reporting for Amvuttra, Onpattro, Oxlumo and Givlaari, including certain fee and discount arrangements with distributors.

• ALNY is feeling the pressure from bearish momentum. See the market dynamics here.

The company reported a third-quarter 2025 adjusted earnings of $2.90, a turnaround from a loss of 50 cents a year ago. Analysts estimated earnings of 75 cents.

The company reported quarterly sales of $1.25 billion, up 149% year over year, beating the consensus of $977.79 million.

Total net product revenues increased 103% (+99% at constant currency), primarily due to growth from Amvuttra, driven by increased ...